sPLA2 inhibitor (IMAGE)
Caption
In tumorigenesis, sPLA2 is secreted by tumor-associated macrophages in tumor tissue. When the membrane phospholipids of EVs secreted from tumor cells are modified by sPLA2, various fatty acids and lysophospholipids are liberated, leading to changes in EV morphology and GPCR signaling enhancement, accelerated uptake, etc. are induced. As a result, the establishment of the tumor microenvironment is rapidly accelerated, leading to tumorigenesis. In contrast, inhibition of this sPLA2-EV axis by varespladib, an sPLA2 inhibitor, suppressed tumor formation. Thus, the sPLA2-EV axis may be a novel drug target for cancer therapy.
Credit
Kai Kudo
Usage Restrictions
None
License
Original content